CASI Pharmaceuticals Appoints Daniel Lang as New CFO and SVP
CASI Pharmaceuticals, Inc. has appointed Daniel Lang, MD as Chief Financial Officer and Senior Vice President.
CASI Pharmaceuticals | 09/07/2024 | By Aishwarya | 444
CASI Pharmaceuticals Plans to Submit IND Application For CID-103
CASI Pharmaceuticals, Inc. has planned to submit an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for CID-103 for the treatment of antibody-mediated rejection (AMR) in kidney transplant recipients by the end of 2024.
CASI Pharmaceuticals | 28/06/2024 | By Aishwarya | 390
CASI Pharmaceuticals Advances CID-103 into Clinical Development for Chronic Immune Thrombocytopenia
CASI received a letter from the FDA indicating clearance for the study to proceed, signaling regulatory approval for the advancement of CID-103 into clinical trials.
CASI Pharmaceuticals | 16/05/2024 | By Abha | 372
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy